Multisystem approach beats single-target therapies for autism in preclinical models

This systematic review examined 52 preclinical studies (2010-2025) investigating pharmacological and microbiota-based treatments for autism spectrum disorder (ASD), with cannabinoids identified as one of several emerging therapeutic classes. The research synthesized evidence across diverse intervention strategies including oxytocinergic agents, excitatory/inhibitory (E/I) balance modifiers, metabolic drugs, cannabinoid-based therapies, purine interventions, and gut-microbiota approaches like probiotics and fecal microbiota transplantation. The studies collectively demonstrate that ASD-like behavioral deficits in animal models respond to treatments targeting multiple biological systems—including neurotransmission, neuroinflammation, metabolism, and the gut-brain axis.

A critical finding is that no single-target approach appears sufficient for treating ASD's complex etiology. The review highlights that traditional narrowly-focused drug development may have limited effectiveness because ASD arises from a network of interconnected systemic processes rather than isolated molecular defects. Cannabinoids, alongside other pharmacological classes, showed promise in preclinical models, suggesting they may modulate behavioral outcomes through effects on neuroinflammation and neurotransmitter signaling. However, the authors identified significant translational gaps between animal research and human clinical application, including methodological inconsistencies, outcome measure variability, and incomplete reporting—challenges that affect the reliability of moving any preclinical finding to clinical practice.

These findings support a paradigm shift toward multisystemic, integrated therapeutic approaches rather than single-agent treatments. For cannabis research specifically, this suggests cannabinoid-based interventions for ASD warrant investigation within coordinated treatment frameworks that address the broader biological dysfunction network, not as standalone solutions. The review underscores the need for more rigorous, standardized preclinical research methods to improve translation of promising therapeutic candidates into effective human treatments.